公开(公告)号：US09956291B2

公开(公告)日：2018-05-01

申请号：US13938308

申请日：2013-07-10

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K47/26 ,  A61K47/12 ,  A61K31/455 ,  A61K31/197 ,  A61K31/192 ,  A61K45/06 ,  A61K31/19 ,  A61K31/198 ,  A61K31/7032 ,  A61K49/00 ,  A61K47/54 ,  A61K47/69

CPC classification number: A61K47/26 ,  A61K31/19 ,  A61K31/198 ,  A61K31/7032 ,  A61K45/06 ,  A61K47/542 ,  A61K47/6937 ,  A61K47/6939 ,  A61K49/0093

Abstract: A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TRβ1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TRβ1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.

公开(公告)号：US09707318B2

公开(公告)日：2017-07-18

申请号：US12912853

申请日：2010-10-27

Applicant: Shaker A. Mousa ,  Mohammed H. Qari ,  Mohammed S. Ardawi

Inventor： Shaker A. Mousa ,  Mohammed H. Qari ,  Mohammed S. Ardawi

IPC: A61F2/00 ,  A01N63/00 ,  A61L27/38 ,  A61L27/10 ,  A61L27/20 ,  A61F2/28

CPC classification number: A61L27/3821 ,  A61F2/2846 ,  A61F2002/2817 ,  A61L27/10 ,  A61L27/20 ,  A61L2430/02

Abstract: A bone patch and method for treating a bone condition of an animal. The bone patch includes a composition of ingredients. The composition of ingredients include: stem cells; signaling molecules for osteoblast/endothelial differentiation; and scaffold material. The method for treating a bone condition includes: applying the bone patch to the animal for bone regeneration, treatment of a fractured bone, and/or treatment of a bone disorder.

公开(公告)号：US09700042B2

公开(公告)日：2017-07-11

申请号：US14614849

申请日：2015-02-05

Applicant: Shaker A. Mousa ,  Amna Saddiq

Inventor： Shaker A. Mousa ,  Amna Saddiq

IPC: A01N25/10 ,  A01N25/28

CPC classification number: A01N25/28 ,  A01N35/04 ,  A01N63/02

Abstract: The composition of the Nano carrier or Nano polymers composed of Hyaluronic Acid (15-25%) and fatty acids (50-70%) cross linked with ultra-Low molecular weight chitosan (15-25%) encapsulating isolated compounds from musk and their combinations for cosmetic use as anti-aging, anti-microbial, and fragrance. Additionally, these nano-encapsulated Musk bioactive compounds (MBC) at 0.1-10% (w/w MBC/Nano polymers) could be used in textile manufacturing (carpet/rugs and clothes) to provide anti-microbial and fragrance properties. Furthermore, Musk derived products are chemically conjugated to HA polymer, FA polymer, CH polymer, HA-CH co-polymer, FA-CH co-polymer or HA-CH-FA co-polymer to be incorporated into the fabric of the textile products (carpet/rugs or clothes).

公开(公告)号：US20140037722A1

公开(公告)日：2014-02-06

申请号：US13953888

申请日：2013-07-30

Applicant: Shaker A. Mousa ,  Abdulqader Al Haider ,  Abdelgalil Abdelgader ,  Abdullah M. Aldahmash ,  Abdulkareem Almomen

Inventor： Shaker A. Mousa ,  Abdulqader Al Haider ,  Abdelgalil Abdelgader ,  Abdullah M. Aldahmash ,  Abdulkareem Almomen

IPC: A61K9/48 ,  A61K47/42 ,  A61K31/727 ,  A61K31/704 ,  A61K31/12 ,  A23C9/152 ,  A61K31/337

CPC classification number: A61K9/4866 ,  A23C9/152 ,  A23C2260/152 ,  A23G9/00 ,  A23L33/19 ,  A23P10/30 ,  A23V2002/00 ,  A61K8/0283 ,  A61K8/63 ,  A61K8/64 ,  A61K8/73 ,  A61K8/736 ,  A61K9/5153 ,  A61K9/5169 ,  A61K31/12 ,  A61K31/337 ,  A61K31/704 ,  A61K31/726 ,  A61K31/727 ,  A61K31/728 ,  A61K31/738 ,  A61K38/00 ,  A61K47/42 ,  A61K47/644 ,  A61K47/68 ,  A61K47/6929 ,  A61K47/6937 ,  A61K2800/413 ,  A61Q11/00 ,  A23V2200/25 ,  A23V2250/54246 ,  A23V2250/54248

Abstract: The present invention provides a composition, a dairy product, and a method for treating a disorder in a subject. The composition includes (i) polymeric nanoparticles and (ii) camel derived glycosaminoglycans (GAG)s ionic complex encapsulated into the nanoparticles, at least one active ingredient encapsulated into the nanoparticles, or combinations thereof. The nanoparticles are lactoferrin nanoparticles including camel derived lactoferrin, casein nanoparticles including camel derived casein, or combinations thereof. The dairy product includes ice cream or frozen yogurt, wherein the ice cream or frozen yogurt includes the composition and is derived from camel milk or other species of milk. The method for treating a disorder in a subject includes administering a therapeutic dose of the composition to the subject.

Abstract translation: 本发明提供组合物，乳制品和治疗受试者中的病症的方法。 组合物包括（i）聚​​合物纳米颗粒和（ii）包封在纳米颗粒中的骆驼衍生的糖胺聚糖（GAG）离子络合物，包封到纳米颗粒中的至少一种活性成分或其组合。 纳米颗粒是乳铁蛋白纳米颗粒，包括骆驼衍生的乳铁蛋白，酪蛋白纳米颗粒，包括骆驼衍生的酪蛋白，或其组合。 乳制品包括冰淇淋或冷冻酸奶，其中冰淇淋或冷冻酸奶包括该组合物并且来自骆驼乳或其它种类的牛奶。 用于治疗受试者中的病症的方法包括向受试者施用治疗剂量的组合物。

公开(公告)号：US20140017329A1

公开(公告)日：2014-01-16

申请号：US13938308

申请日：2013-07-10

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K47/26 ,  A61K47/12 ,  A61K31/455 ,  A61K31/197 ,  A61K31/192

CPC classification number: A61K47/26 ,  A61K31/19 ,  A61K31/198 ,  A61K31/7032 ,  A61K45/06 ,  A61K47/542 ,  A61K47/6937 ,  A61K47/6939 ,  A61K49/0093

Abstract: A composition and an associated method for hepatic targeted delivery of thyroid receptor beta1 (TRβ1) agonist to a liver of a subject. The composition includes hydrophobic nanoparticles, a liver targeting moiety exterior to each nanoparticle and covalently bonded to each nanoparticle, and at least one TRβ1 agonist encapsulated within each nanoparticle. The nanoparticles include chitosan hybrid nanoparticles, amine-modified PLGA nanoparticles, solid lipid nanoparticles, and combinations thereof. The liver targeting moiety includes Glycyrrhetinic acid (GA), Lactobionic acid (LA), or combinations thereof.

Abstract translation: 用于肝脏靶向递送甲状腺受体β1（TRbeta1）激动剂到受试者肝脏的组合物和相关方法。 组合物包括疏水性纳米颗粒，每个纳米颗粒外部的共价键合到每个纳米颗粒上的肝靶向部分，以及封装在每个纳米颗粒内的至少一种TRβ1激动剂。 纳米颗粒包括壳聚糖杂化纳米颗粒，胺改性的PLGA纳米颗粒，固体脂质纳米颗粒及其组合。 肝靶向部分包括甘草次酸（GA），乳酸（LA）或其组合。

公开(公告)号：US20130295187A1

公开(公告)日：2013-11-07

申请号：US13935665

申请日：2013-07-05

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K47/48 ,  A61K31/437 ,  A61K31/4245 ,  A61K9/50 ,  A61K31/195

CPC classification number: A61K47/48315 ,  A61K9/5031 ,  A61K9/5036 ,  A61K31/195 ,  A61K31/4245 ,  A61K31/437 ,  A61K38/4846 ,  A61K47/645 ,  A61K47/6929 ,  C12N9/6437

Abstract: A method for treating a subject, such as a human patient, having a vascular disorder. The treatment method administers a therapeutic effective amount of a nanoparticle or a chemical structure to the subject to treat the disorders. The nanoparticle includes a poly L-arginine polymer and a Factor VIIa inhibitor conjugated to, or encapsulated in, the poly L-arginine polymer. The chemical structure includes a Factor VIIa inhibitor that includes at least one nitric oxide (NO) donor. The disorder may be sickle cell disease; stimulated or pathological angiogenesis associated disorders, cancer, ocular angiogenesis-mediated disorders such as diabetic retinopathy and macular degeneration, coagulation and/or platelet activation-associated disorders, pulmonary hypertension, or combinations thereof.

Abstract translation: 用于治疗患有血管病症的受试者例如人类患者的方法。 治疗方法向受试者施用治疗有效量的纳米颗粒或化学结构以治疗疾病。 纳米颗粒包括聚L-精氨酸聚合物和与聚L-精氨酸聚合物缀合或封装的因子VIIa抑制因子。 该化学结构包括包含至少一种一氧化氮（NO）供体的因子VIIa抑制剂。 该病可能是镰状细胞病; 刺激或病理性血管生成相关疾病，癌症，眼血管生成介导的病症如糖尿病性视网膜病变和黄斑变性，凝血和/或血小板活化相关疾病，肺动脉高压或其组合。

公开(公告)号：US20120258069A1

公开(公告)日：2012-10-11

申请号：US13156047

申请日：2011-06-08

Applicant: Maria Alexander-Bridges ,  Shaker A. Mousa ,  Paul J. Davis

Inventor： Maria Alexander-Bridges ,  Shaker A. Mousa ,  Paul J. Davis

IPC: C08G63/91 ,  A61P3/00 ,  C40B30/06 ,  G01N33/566 ,  C40B30/04 ,  C12Q1/68 ,  A61K47/48 ,  A61P5/48

CPC classification number: G01N33/5023 ,  A61K47/58 ,  A61K47/593 ,  A61K47/60 ,  A61K47/61 ,  C12N15/1086

Abstract: Provided herein are compositions and methods for preventing and treating diseases and risk factors associated with metabolic syndrome by targeting the RGD-binding site of selected intra- and extracellular proteins. Exemplary compositions include RGD-polyphenol conjugates via an ester linkage; polyphenol polymer conjugated to RGD analogs or mimetics; and RGD polymer conjugates linked to polyphenol.

Abstract translation: 本文提供了通过靶向选择的细胞外和细胞外蛋白质的RGD结合位点来预防和治疗与代谢综合征相关的疾病和危险因素的组合物和方法。 典型的组合物包括通过酯键的RGD-多酚共轭物; 与RGD类似物或模拟物缀合的多酚聚合物; 和与多酚连接的RGD聚合物缀合物。

公开(公告)号：US08071134B2

公开(公告)日：2011-12-06

申请号：US11663047

申请日：2005-09-15

Applicant: Shaker A. Mousa ,  Faith B. Davis ,  Paul J. Davis

Inventor： Shaker A. Mousa ,  Faith B. Davis ,  Paul J. Davis

IPC: A61K9/14 ,  A61K9/50 ,  A61K3/21

CPC classification number: A61K31/192 ,  A61K31/195 ,  A61K31/4365 ,  A61K31/60 ,  A61K31/7076 ,  A61K31/727 ,  A61K38/1825 ,  A61K38/1866 ,  A61K47/58 ,  A61K47/593 ,  A61K47/60 ,  A61K47/61 ,  A61K47/64 ,  A61K49/0008 ,  A61K49/085 ,  A61K49/10 ,  A61K49/12 ,  A61K51/0402 ,  A61K51/0497 ,  A61K51/065 ,  A61L27/34 ,  A61L27/54 ,  A61L29/085 ,  A61L29/16 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/43 ,  A61L2300/606 ,  A61K2300/00

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Abstract translation: 公开了治疗具有与血管发生相关的病症的受试者的方法，包括施用有效量的甲状腺激素或其拮抗剂的聚合形式，以促进或抑制受试者的血管生成。 还公开了甲状腺激素或甲状腺激素类似物的聚合形式的组合物。

公开(公告)号：US20110105482A1

公开(公告)日：2011-05-05

申请号：US12916714

申请日：2010-11-01

Applicant: Shaker A. Mousa

Inventor： Shaker A. Mousa

IPC: A61K31/54 ,  C07C229/34 ,  A61K31/195 ,  C07D295/155 ,  C07D213/55 ,  A61K31/4406 ,  A61K31/24 ,  C07C271/22 ,  A61K31/27 ,  A61P29/00 ,  A61P27/02 ,  A61P35/00 ,  A61P5/00

CPC classification number: C07D279/12 ,  A61K31/195 ,  A61K31/24 ,  A61K31/27 ,  A61K31/4406 ,  A61K31/54 ,  C07C217/20 ,  C07C239/12 ,  C07C271/16 ,  C07C271/22 ,  C07C275/24 ,  C07C279/08 ,  C07D213/36 ,  C07D213/55 ,  C07D295/155

Abstract: A dual thyrointegrin antagonist and a method for treating an angiogenesis-mediated disorder and/or a hyperthyroidism disorders by introducing the dual thyrointegrin antagonist into animals (e.g., mammals, human beings). The dual thyrointegrin antagonist includes a chemical structure having a thyroid hormone antagonist and αvβ3 integrin antagonist in the same molecule.

Abstract translation: 双重甲状腺整合素拮抗剂和通过将双重甲状腺整合素拮抗剂引入动物（例如哺乳动物，人）中来治疗血管生成介导的病症和/或甲状腺功能亢进症的方法。 双重甲状腺整合素拮抗剂包括在同一分子中具有甲状腺激素拮抗剂和αv＆bgr 3整合素拮抗剂的化学结构。

公开(公告)号：US06346517B1

公开(公告)日：2002-02-12

申请号：US09523395

申请日：2000-03-10

Applicant: Pancras C. Wong ,  Shaker A. Mousa

Inventor： Pancras C. Wong ,  Shaker A. Mousa

IPC: A61K31725

CPC classification number: A61K31/727 ,  A61K31/42 ,  A61K31/60 ,  A61K31/715 ,  A61K39/39541 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2848 ,  A61K2300/00

Abstract: This invention is directed to a combination therapy comprising the administration of a low molecular weight heparin such as tinzaparin and a platelet GPIIb/IIIa antagonist such as roxifiban for treating, preventing and reducing the risk of thromboembolic disorders.

Abstract translation: 本发明涉及包括施用低分子量肝素如锡扎肝素和血小板GPIIb / IIIa拮抗剂如罗西非班的组合疗法，用于治疗，预防和降低血栓栓塞障碍的风险。